John Ambroseo, Präsident und Coherent's CEO (Chief Executive Officer) stellt fest: "Durch den Kauf dieser beiden Produktlinien erhalten wir Zugang zum Markt der maschinellen Visualisierung, und erweitern mit den Diodenlasermodulen unsere Möglichkeiten im Marktsegment der Bioinstrumentation. Ferner erhalten wir mit der Akquisition eine Faser-Schlüsseltechnologie, die es uns ermöglichen wird, faserbasierende Produkte schneller in den Markt zu bringen, und sowohl deren Performance als auch deren Zuverlässigkeit weiter zu entwickeln".
Forward-Looking Statements
This press release contains forward-looking statements, as defined under the Federal securities laws. These forward-looking statements include the statements in this press release that relate to improving Coherent's time to market and enhancement to both the performance and reliability of our fiber-based product platforms. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. Factors that could cause actual results to differ materially include risks and uncertainties, including, but not limited to, risks associated with integration and continued development of the acquired assets and existing and resulting product platforms, and other risks identified in the Company's SEC filings. Readers are encouraged to refer to the risk disclosures described in the Company's reports on Forms 10-K, 10-Q and 8-K, as applicable and as filed from time-to-time by the Company. Actual results, events and performance may differ materially from those presented herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update these forward-looking statements as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.